ArticleDiscover oncology2026
Prognostic Nutritional Index enhances risk stratification and predicts progression-free survival in upper tract urothelial carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe management of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) is hampered by heterogeneous outcomes and a lack of robust, integrative biomarkers. The Prognostic Nutritional Index (PNI), reflecting both nutritional status and systemic immunity, has emerged as a prognostic tool in various cancers, but its utility in UTUC remains underexplored.
objectiveTo comprehensively evaluate the prognostic value of preoperative PNI and to develop a validated nomogram for predicting progression-free survival (PFS) in UTUC patients undergoing RNU.
methodsIn this retrospective cohort study, 200 consecutive UTUC patients treated with RNU (2016–2020) were analyzed. The PNI was calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per μL). Receiver operating characteristic (ROC) curve analysis determined the optimal PNI cut-off. Survival analyses were performed using Kaplan–Meier and Cox proportional hazards models. A nomogram integrating independent predictors was developed and subjected to internal validation with bootstrapping, assessing discrimination, calibration, and clinical utility.
resultsThe optimal PNI cut-off was 46.0, demonstrating high predictive accuracy for recurrence (area under the curve [AUC] = 0.866). Patients with low PNI (< 46.0) had significantly inferior PFS (median PFS: 32 vs. 58 months; log-rank P = 0.002). Multivariate analysis identified low PNI (Hazard Ratio [HR] = 1.96, 95% Confidence Interval [CI]: 1.33–2.88, P < 0.001), tumor size ≥ 3 cm (HR = 1.84, 95% CI: 1.06–3.20, P = 0.030), multifocality (HR = 1.80, 95% CI: 1.09–2.97, P = 0.021), high-grade pathology (HR = 1.68, 95% CI: 1.03–2.73, P = 0.037), and advanced T stage (pT3/T4) as independent predictors of poor PFS. The resultant nomogram exhibited good discriminative ability, with an AUC of 0.903 for predicting 3-year PFS, and provided a positive net benefit on decision curve analysis.
conclusionPreoperative PNI may serve as a potent, independent prognostic factor for UTUC. The integrated nomogram demonstrates good predictive accuracy and facilitates personalized risk assessment, potentially guiding adjuvant therapy decisions and postoperative surveillance strategies. The modifiable nature of PNI also opens avenues for nutritional and immunomodulatory interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.